Trials / Completed
CompletedNCT05025085
A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors
A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Agenus Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AGEN1777 as a single agent and when used in combination with a PD-1 inhibitor in participants with advanced, metastatic solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGEN1777 | An immunoglobulin gamma (IgG1) antibody |
| DRUG | a PD-1 inhibitor | Anti-programmed cell death protein 1 (Anti-PD-1) antibody monoclonal antibody |
Timeline
- Start date
- 2021-10-04
- Primary completion
- 2023-07-11
- Completion
- 2024-04-01
- First posted
- 2021-08-27
- Last updated
- 2025-10-15
Locations
11 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05025085. Inclusion in this directory is not an endorsement.